- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01090986
Home Mechanical Ventilation Effectiveness and Air Leaks
February 21, 2014 updated by: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Prediction of Home Mechanical Ventilation Effectiveness by Means of Non-controlled Air Leaks Estimation.
Non invasive ventilation (NIV) usually presents air leaks that may determine the result of this treatment.
The clinical usefulness of analyzing (and quantifying) these leaks during the adaptation period to NIV has not been evaluated in prospective clinical studies as a predictive data of treatment effectiveness.
Our hypothesis is that air leaks are correlated to a successful adaptation to NIV.
And air leak magnitude may predict early failures of this treatment.
And also, as we do not know if air leaks change during the adaptation period to NIV, we do not know whether early detection of air leaks plays a role in the therapeutic outcome.
Our objective is to evaluate the clinical usefulness of quantifying air leaks during the adaptation period to NIV as a predictor of effectiveness of this treatment.
We also want to evaluate the correlation between air leaks and clinical-functional patients' profile, and the ventilatory parameters selected and to evaluate air leaks variability during the adaptation period to NIV.
Method: We will determine the air leak magnitude in twenty patients during adaptation to NIV.
We will use VPAP III ventilators (ResMed, Australia), commercial nasal masks (Mirage o Ultra Mirage) and VPAP III/ResLinkTM (ResMed, North Ryde, Australia), a device that includes a monitoring system coupled with the VPAP III ventilator.
This device allows to record air leaks and other ventilation parameters.
We will perform four VPAP III/ResLinkTM recordings in each patient (the last night in hospital during the adaptation period, the first night at home, and one and two months later, after the initiation of NIV treatment).
We will also perform a complete pulmonary function test, quality-of-life questionnaire (SF36), and a tolerance to NIV questionnaire in all patients at the onset of NIV treatment and two months later.
We will evaluate which patients will need to change treatment at the end of the adaptation period to NIV.
We also will analyze and compare air leaks magnitude in each of the four recordings stated above.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
20
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Barcelona, Spain, 08025
- Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
- Patients with a restrictive pulmonary disease (slow evolution neuromuscular or thorax cage diseases, obesity or nocturnal hypoventilation) and hypercapnic chronic respiratory failure with standard criteria for NIV.
- Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
Description
Inclusion Criteria:
- Patients with a restrictive pulmonary disease (slow evolution neuromuscular or thorax cage diseases, obesity or nocturnal hypoventilation) and hypercapnic chronic respiratory failure with standard criteria for NIV.
- COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
- PaCO2 ≥ de 50 mmHg.
- Clinically stable (at least for one month).
- Possibility to fit a nasal mask for NIV treatment (ultra mirage, mirage).
Exclusion Criteria:
- Rapid evolution neuromuscular disease (Amyotrophic Lateral Sclerosis).
- Serious comorbidity.
- Lack of patients comprehension or collaboration.
- Inability to fit a nasal mask for NIV treatment (ultra mirage, mirage).
- Treatment compliance < 4h/d.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
1
Patients with a restrictive pulmonary disease and hypercapnic chronic respiratory failure with standard criteria for NIV.
Also COPD patients who need NIV because of another reason (obesity, nocturnal hyperventilation or nocturnal hypercapnic response to oxygen).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Clinical usefulness of quantifying AIR LEAKS during the adaptation period to NIV as a predictor of effectiveness (pCO2 EVOLUTION) of this treatment.
Time Frame: One year
|
One year
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
- Air leaks AND patients' characteristics.- Some indices (air leaks/inspiratory pressure...)and NIV effectiveness. - Air leak evolution.- Air leaks and patients' tolerance to NIV.
Time Frame: One year
|
One year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Carme Puy, MD, Hospital Santa Creu i Sant Pau
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2006
Primary Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
March 19, 2010
First Submitted That Met QC Criteria
March 22, 2010
First Posted (Estimate)
March 23, 2010
Study Record Updates
Last Update Posted (Estimate)
February 24, 2014
Last Update Submitted That Met QC Criteria
February 21, 2014
Last Verified
February 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR02/02/2007
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
-
Mylan Inc.Theravance BiopharmaCompletedChronic Obstructive Pulmonary Disease, COPDNew Zealand
-
Astellas Pharma Global Development, Inc.CytokineticsCompletedChronic Obstructive Pulmonary Disease (COPD)United States
-
AstraZenecaParexel International Ltd; Cognizant Technology Solution; Center for Information... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease COPDUnited States, Canada, France, Russian Federation, Ukraine, Hungary, Bulgaria
-
University of ZurichNational Center of Cardiology and Internal Medicine named after academician...CompletedChronic Obstructive Pulmonary Disease (COPD)Kyrgyzstan